Summary

Dr. Massimo Gadina is the Director of the Office of Science and Technology (OST) at the NIAMS, supporting intramural researchers with core technologies. He also serves as Chief of the Translational Immunology Section of the OST. Prior to this appointment, he was Senior Lecturer at the Division of Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, The Queen's University of Belfast, Northern Ireland.

Research Statement

Dr. Gadina's research interests are focused on immune-mediated diseases and specifically, the biology of cytokines and their relative signaling pathways. His translational work is also focused on autoinflammatory diseases and other inflammatory diseases.

Scientific Publications

A Decade of Jakinibs: what have we learned and what may be the future.

Liu C, Kieltyka J, Fleischmann R, Gadina M, O'Shea JJ
Arthritis Rheumatol.
2021 Jun 27;
doi: 10.1002/art.41906
PMID: 34180156

JAK inhibitors: Ten years after.

Spinelli FR, Meylan F, O'Shea JJ, Gadina M
Eur J Immunol.
2021 Jul;
51(7).
doi: 10.1002/eji.202048922
PMID: 33930196

Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.

Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, Balanda N, Ross DL, Ospina Cardona D, Wu Z, Patel B, Manthiram K, Groarke EM, Gutierrez-Rodrigues F, Hoffmann P, Rosenzweig S, Nakabo S, Dillon LW, Hourigan CS, Tsai WL, Gupta S, Carmona-Rivera C, Asmar AJ, Xu L, Oda H, Goodspeed W, Barron KS, Nehrebecky M, Jones A, Laird RS, Deuitch N, Rowczenio D, Rominger E, Wells KV, Lee CR, Wang W, Trick M, Mullikin J, Wigerblad G, Brooks S, Dell'Orso S, Deng Z, Chae JJ, Dulau-Florea A, Malicdan MCV, Novacic D, Colbert RA, Kaplan MJ, Gadina M, Savic S, Lachmann HJ, Abu-Asab M, Solomon BD, Retterer K, Gahl WA, Burgess SM, Aksentijevich I, Young NS, Calvo KR, Werner A, Kastner DL, Grayson PC
N Engl J Med.
2020 Dec 31;
383(27).
doi: 10.1056/NEJMoa2026834
PMID: 33108101

Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.

Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA
Ann Rheum Dis.
2020 Aug 25;
pii: annrheumdis-2020-218690. doi: 10.1136/annrheumdis-2020-218690
PMID: 32843325

HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.

Spinelli FR, Conti F, Gadina M
Sci Immunol.
2020 May 8;
5(47).
pii: eabc5367. doi: 10.1126/sciimmunol.abc5367
PMID: 32385052

Translating JAKs to Jakinibs.

Gadina M, Chisolm DA, Philips RL, McInness IB, Changelian PS, O'Shea JJ
J Immunol.
2020 Apr 15;
204(8).
doi: 10.4049/jimmunol.1901477
PMID: 32253269

JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis.

Vian L, Le MT, Gazaniga N, Kieltyka J, Liu C, Pietropaolo G, Dell'Orso S, Brooks SR, Furumoto Y, Thomas CJ, O'Shea JJ, Sciumè G, Gadina M
Front Immunol.
2019;
10().
doi: 10.3389/fimmu.2019.02972
PMID: 31921209

Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease.

Lalaoui N, Boyden SE, Oda H, Wood GM, Stone DL, Chau D, Liu L, Stoffels M, Kratina T, Lawlor KE, Zaal KJM, Hoffmann PM, Etemadi N, Shield-Artin K, Biben C, Tsai WL, Blake MD, Kuehn HS, Yang D, Anderton H, Silke N, Wachsmuth L, Zheng L, Moura NS, Beck DB, Gutierrez-Cruz G, Ombrello AK, Pinto-Patarroyo GP, Kueh AJ, Herold MJ, Hall C, Wang H, Chae JJ, Dmitrieva NI, McKenzie M, Light A, Barham BK, Jones A, Romeo TM, Zhou Q, Aksentijevich I, Mullikin JC, Gross AJ, Shum AK, Hawkins ED, Masters SL, Lenardo MJ, Boehm M, Rosenzweig SD, Pasparakis M, Voss AK, Gadina M, Kastner DL, Silke J
Nature.
2020 Jan;
577(7788).
doi: 10.1038/s41586-019-1828-5
PMID: 31827281

High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis.

Tsai WL, Vian L, Giudice V, Kieltyka J, Liu C, Fonseca V, Gazaniga N, Gao S, Kajigaya S, Young NS, Biancotto A, Gadina M
J Immunol Methods.
2020 Feb;
477().
doi: 10.1016/j.jim.2019.112667
PMID: 31726053

Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.

Simon N, Antignani A, Hewitt SM, Gadina M, Alewine C, FitzGerald D
JCI Insight.
2019 Mar 7;
4(5).
pii: 123281. doi: 10.1172/jci.insight.123281
PMID: 30720466

Selective Janus kinase inhibitors come of age.

O'Shea JJ, Gadina M
Nat Rev Rheumatol.
2019 Feb;
15(2).
doi: 10.1038/s41584-018-0155-9
PMID: 30622297

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.

Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R
J Clin Invest.
2018 Jul 2;
128(7).
doi: 10.1172/JCI98814
PMID: 29649002

Education

Università di Milano, Italy
Doctor of Pharmaceutical Chemistry and Technology

Université de Bourgogne, Dijon, France
Diplôme de Docteur

Experience

Director, Office of Science and Technology
Chief, Translational Immunology Section
NIAMS, NIH, 2009 - present

Staff Scientist, Acting Director, Office of Science and Technology
Acting Chief Translational Immunology Section
NIAMS, NIH, 2008 - 2009

Senior Lecturer, Tenured
Division of Infection and Immunity, School of Medicine Dentistry and Biomedical Sciences, The Queen’s University of Belfast, Northern Ireland, U.K., 2003 - 2008

Staff Scientist
Lymphocyte Cell Biology Section, Arthritis and Rheumatism Branch, NIAMS, NIH, 2000 - 2002

Visiting Associate
Lymphocyte Cell Biology Section, Arthritis and Rheumatism Branch, NIAMS, NIH, 1996 - 1999

Research Associate-Staff Scientist
Division of Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori,Milano, Italy, 1990 - 1996.

Last Updated: September 2021